Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China.
Complement Ther Med. 2019 Apr;43:208-217. doi: 10.1016/j.ctim.2019.01.019. Epub 2019 Feb 8.
The severity of angina pectoris has been recognized. It is believed that Chinese herbal injections have an outstanding clinical effect on this condition. This network meta-analysis was devised to investigate the comparative efficacy of eight Chinese herbal injections (Ciwujia injection, Dazhuhongjingtan injection, Huangqi injection, Shenfu injection, Shengmai injection, Shenmai injection, Shenqi Fuzheng injection, Yiqifumai injection) in the treatment of angina pectoris.
A literature search was performed in PubMed, Embase, and the Cochrane Library, Chinese Biological Medicine Database, China National Knowledge Infrastructure, Wanfang Database, and Chinese Scientific Journal Database from their inception to June 25, 2018. A pre-designed eligibility criterion was utilized in this network meta-analysis, and a methodological quality analysis was conducted. Data analysis was performed by WinGUGS 1.4.3, Stata 13.0 and TSA software, and the odds ratio or mean difference with the 95% credible interval was reported for symptomatic improvement, electrocardiography improvement, fibrinogen, triglyceride and cholesterol. The ranking probability of interventions in various outcomes was also utilized.
A total of 73 randomized controlled trials with 6639 patients were identified. Integrating network meta-analysis results, Shenqi Fuzheng injection plus western medicine therapy and Shenmai injection plus western medicine therapy were shown to be more efficacious than other therapies. In addition, Huangqi injection plus western medicine therapy and Shenmai injection plus western medicine therapy performed well in improving the haemorheology index and serum lipid parameters.
Eligible Chinese herbal injections plus western medicine therapy might have a better impact on angina pectoris patients than western medicine therapy alone. While this study had limitations, the findings should be interpreted with caution. In addition, more high-quality randomized controlled trials with a large sample must be conducted to support this study.
心绞痛的严重程度已得到公认。人们认为中药注射剂对这种疾病具有突出的临床疗效。本网络荟萃分析旨在研究 8 种中药注射剂（刺五加注射液、大株红景天注射液、黄芪注射液、参附注射液、生脉注射液、参麦注射液、参芪扶正注射液、益气复脉注射液）治疗心绞痛的疗效比较。
检索 PubMed、Embase 和 Cochrane 图书馆、中国生物医学文献数据库、中国知网、万方数据库和中国科学期刊数据库，从建库到 2018 年 6 月 25 日。本网络荟萃分析采用预先设计的纳入标准，并进行方法学质量分析。采用 WinBUGS 1.4.3、Stata 13.0 和 TSA 软件进行数据分析，报告症状改善、心电图改善、纤维蛋白原、甘油三酯和胆固醇的比值比或均数差值及 95%可信区间。还利用干预措施在各种结局中的排序概率。
共纳入 73 项随机对照试验，6639 例患者。整合网络荟萃分析结果显示，参芪扶正注射液联合西药治疗和参麦注射液联合西药治疗的疗效优于其他治疗方法。此外，黄芪注射液联合西药治疗和参麦注射液联合西药治疗在改善血液流变学指标和血清脂质参数方面效果较好。
与单纯西药治疗相比，合格的中药注射剂联合西药治疗可能对心绞痛患者有更好的影响。虽然本研究存在局限性，但应谨慎解释研究结果。此外，还需要开展更多高质量、大样本的随机对照试验来支持本研究。
